SCHEMBL4118596

SCHEMBL4118596

O=C(O)Nc1ccc(Cl)cc1C(O)c1cccc2c1OCCO2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 4/20 0.46
NPC1 O15118 8/20 0.40
RAB9A P51151 7/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MAOB P27338 2/20 0.37
KDM4E B2RXH2 3/20 0.37
EGFR P00533 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MRGPRX1 Q96LB2 1/20 0.35
MTNR1A P48039 1/20 0.35
MAPT P10636 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4119063 0.85 PARP1 (0.39) FDFT1NPC1L3MBTL1KDM4ESMN1; SMN2
SCHEMBL4118772 0.85 FDFT1 (0.44) FDFT1NPC1RAB9AL3MBTL1MAOB
SCHEMBL7237652 0.80 FDFT1 (0.50) FDFT1MTNR1AMAPT
SCHEMBL4245267 0.79 FDFT1 (0.40) FDFT1NPC1RAB9AL3MBTL1KDM4E
SCHEMBL4118209 0.78 FDFT1 (0.43) FDFT1NPC1RAB9AMAOBKDM4E
SCHEMBL4129117 0.77 LPAR1 (0.38) FDFT1KDM4EEGFRSMN1; SMN2ALDH1A1
SCHEMBL4124853 0.77 MAPT (0.46) NPC1RAB9AKDM4EEGFRALDH1A1
SCHEMBL18287933 0.75 KDM4E (0.45) FDFT1KDM4ESMN1; SMN2MTNR1A
SCHEMBL4121438 0.75 MEN1 (0.46) RAB9AKDM4EALDH1A1MEN1KMT2A
SCHEMBL4113798 0.74 GRIK1 (0.47) RAB9AKDM4ESMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR FDFT1 1/4885NPC1 187/4885RAB9A 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.